Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
ABBOTT LABORATORIES (ABT) received a Form 144 notice that John A. McCoy, Jr., identified as an officer, intends to sell 27 shares of common stock under Rule 144. The shares come from a restricted stock award that vested on September 1, 2026 and are to be sold on September 2, 2026 through UBS Financial Services, Inc. on the NYSE.
ABBOTT LABORATORIES (ABT) reported insider transactions by Chairman and CEO Robert B. Ford on 2026-08-25. He exercised employee stock options covering 398,832 common shares (151,869 at a $44.40 exercise price and 246,963 at $59.94), then sold a total of 398,832 common shares in open-market transactions at volume-weighted average prices in the $115–$116 range. In addition, 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
ABBOTT LABORATORIES (ABT) received a Rule 144 notice from Robert B. Ford covering a proposed sale of its common stock. The notice indicates an intention to sell up to 398,832 shares of Abbott common stock through UBS Financial Services, Inc., with sales beginning on or after August 25, 2026. The shares are to be acquired via exercise of stock options for cash before being sold.
Abbott Laboratories (ABT) reported that it has entered into settlement agreements resolving the Missouri Gill case and necrotizing enterocolitis (NEC) claims involving approximately 2,000 additional infants relating to its specialty formulas for preterm infants. The aggregate settlement amount is approximately $670 million, described as a compromise of disputed claims and not an admission of liability.
The company had faced a $495 million jury verdict in the Gill case, which, with accrued interest, would have required payment of about $600 million absent further appeals or settlement. Abbott states it believes the agreements are in its long‑term interest and a constructive step toward substantially resolving the overall litigation. After these agreements, about 1,700 lawsuits remain pending involving claims on behalf of roughly 12,700 infants.
Abbott Laboratories executive Louis H. Morrone, Executive Vice President, reported transactions in common shares. On August 11, 2026, he sold 5,850 common shares in a non-derivative transaction at $109.83 per share, leaving 70,724 common shares held directly. On August 12, 2026, a discretionary transaction under Rule 16b-3(f) disposed of 12 indirectly held shares in a Profit Sharing Trust at $107.99 per share, leaving no shares reported under that indirect ownership.
Abbott Laboratories (ABT) reported a planned sale of common stock under a Form 144. A brokerage account at UBS Financial Services is listed in connection with 5,850 shares of common stock to be sold on the NYSE on or after August 11, 2026. The filing also references vested restricted stock awards dated February 27, 2026 in amounts of 1,960, 1,991, and 1,899 shares as the source of the securities to be sold.
Abbott Laboratories reported strong top-line growth for the quarter ended June 30, 2026. Net sales were $12.593 billion, up 13.0% year over year, with comparable sales growth of 4.8%. GAAP diluted EPS was $0.53 versus $1.01 a year ago, while adjusted diluted EPS, which excludes $1.362 billion of specified after-tax charges including $658 million of intangible amortization and acquisition- and legal-related costs, rose to $1.31 from $1.26.
Diagnostics and Medical Devices led performance, with comparable sales growth of 2.9% and 8.4% respectively, while Established Pharmaceuticals grew 8.7% and Nutrition declined 3.6% on a comparable basis. Abbott completed the acquisition of Exact Sciences, advancing its Cancer Diagnostics business, and highlighted progress in key pipeline programs, including completion of enrollment in the TECTONIC trial, CE Mark for the Libre Duo glucose‑ketone sensor, and FDA submission for the Amulet 360 device.
Management reaffirmed full‑year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full‑year adjusted EPS guidance to $5.45–$5.60, with third‑quarter adjusted EPS projected at $1.38–$1.46. The company returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.
ABBOTT LABORATORIES director John G. Stratton reported a compensation-related grant of stock-based units, not an open-market trade. On the reported date, he acquired 432 stock equivalent units tied to Abbott common shares at a reference value of $90.74 per unit. These units represent director fees credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash around age 65 or upon retirement from the board.
The stock equivalent units earn the same return as if the fees were invested in Abbott shares and the reported balance also reflects units accumulated through a dividend reinvestment feature. Following this grant, Stratton’s account holds a total of 14,022 stock equivalent units.
Roman Michael F reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 416 stock equivalent units as compensation. These units were credited on 2026-06-30 at a reference price of $90.74 per unit and are tied to director fees.
The stock equivalent units track the return Abbott shares would have earned, but are paid out in cash, generally at age 65 or when the director retires from the board. After this award, Roman holds a total of 6,746 stock equivalent units, including amounts accumulated through a dividend reinvestment feature.